Skip to Content
Cancer Therapy Evaluation Program (CTEP)
Contact NExT
Show menu
Search this site
Last Updated: 12/10/21

Richard F. Little, MD

Richard F. Little, MD

Head — Hematologic, HIV, and
Stem Cell Therapeutics

Dr. Richard F. Little joined CTEP in 2007 as head of the therapeutics section for Hematologic and AIDS-related Cancers and Hematopoietic Stem Cell Transplant. His focus is to oversee, review, and coordinate the NCI-sponsored late phase cancer treatment trials in these diseases. Dr. Little serves as lead CTEP reviewer for several NCI-sponsored precision medicine trials including the NCI-MATCH Trial (Molecular Analysis for Therapy Choice), and the second generation of precision medicine studies including ComboMATCH (based on the premise that combination therapy will be more effective than monotherapy utilized in the original MATCH trial), and MyeloMATCH, a portfolio of AML and MDS trials that uses advanced assays to target residual disease with increasing precision as newly diagnosed patients undergo treatment.

Dr. Little received his medical degree from the University of South Carolina in 1989. After completing Residency Training in Internal Medicine at the Boston City Hospital, he completed a combined medical oncology and hematology fellowship in 1994 at the National Heart Lung and Blood Institute and the National Cancer Institute. Dr. Little was recognized as an outstanding teacher and mentor in 2005 when he was nominated for the Distinguished NIH Teacher award.

Contact Information:
National Cancer Institute
9609 Medical Center Dr., MSC 9739
For USPS: Bethesda, MD 20892-9739
For Express and Courier: Rockville, MD 20850
Phone: 240-276-6560
Fax: 240-276-7892

About the Branch Chief

Meg Mooney, MD, MS Meg Mooney, MD, MS, is the Associate Director of the Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis (DCTD), at the National Cancer Institute (NCI), and she is also the Chief of the Clinical Investigations Branch (CIB) in CTEP. More…